ArticleNature communications2023
Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.Bioactive materials · 2026Article
- Near-Infrared Responsive Property and Nanozyme Effect-Mediated 3D-Printed Gradient Bioactive Scaffold for Intelligent Immunomodulation in Regeneration of Large Segmental Bone Defects.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Designing Microbe-Semiconductor Interfaces for Semibiological Photosynthesis.Chemical reviews · 2026Review
- Programming the beating heart with polymer catalysis: a therapeutic microenvironment revolution.Journal of nanobiotechnology · 2026Review
- Living bacterial reactor potently activates tumor immunogenic ferroptosis via cysteine depletion and photothermal therapy.Materials today. Bio · 2026Article
- Advancing prussian blue nanoparticle-mediated photothermal therapy through machine learning and multiomics integration.Nanomedicine (London, England) · 2026Review
- Metal-Organic Frameworks for Precision Phototherapy of Breast Cancer.Molecules (Basel, Switzerland) · 2026Review
- Spatiotemporal control of immunogenic cell death: rewiring tumor-immune dialogues for next-generation immunotherapy.Frontiers in immunology · 2026Review
- Targeted reduction-responsive nanovehicles for photodynamic therapy-primed immunotherapy in melanoma.Journal of pharmaceutical analysis · 2025Article
- Mechanical Biomimetic Nanocomposites for Multidimensional Treatment of Arterial Thrombosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Aggregation induced emission luminogen bacteria hybrid bionic robot for multimodal phototheranostics and immunotherapy.Nature communications · 2025Article
- Multidimensional applications of prussian blue-based nanoparticles in cancer immunotherapy.Journal of nanobiotechnology · 2025Review
- Engineered hypoxia-responsive albumin nanoparticles mediating mitophagy regulation for cancer therapy.Nature communications · 2025Article
- Mitochondria-targeted strategies in tumor immunity.Frontiers in immunology · 2025Review
- Article
- Engineering Shewanella oneidensis-Carbon Felt Biohybrid Electrode Decorated with Bacterial Cellulose Aerogel-Electropolymerized Anthraquinone to Boost Energy and Chemicals Production.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- A Stable Open-Shell Conjugated Diradical Polymer with Ultra-High Photothermal Conversion Efficiency for NIR-II Photo-Immunotherapy of Metastatic Tumor.Nano-micro letters · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy is revolutionizing oncology. The marriage of nanotechnology and immunotherapy offers a great opportunity to amplify antitumor immune response in a safe and effective manner. Here, electrochemically active Shewanella oneidensis MR-1 can be applied to produce FDA-approved Prussian blue nanoparticles on a large-scale. We present a mitochondria-targeting nanoplatform, MiBaMc, which consists of Prussian blue decorated bacteria membrane fragments having further modifications with chlorin e6 and triphenylphosphine. We find that MiBaMc specifically targets mitochondria and induces amplified photo-damages and immunogenic cell death of tumor cells under light irradiation. The released tumor antigens subsequently promote the maturation of dendritic cells in tumor-draining lymph nodes, eliciting T cell-mediated immune response. In two tumor-bearing mouse models using female mice, MiBaMc triggered phototherapy synergizes with anti-PDL1 blocking antibody for enhanced tumor inhibition. Collectively, the present study demonstrates biological precipitation synthetic strategy of targeted nanoparticles holds great potential for the preparation of microbial membrane-based nanoplatforms to boost antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.